Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Bayoumi

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Annals of Internal Medicine|May 23, 1998
The language of case historiesA M Bayoumi, D Bravata
AIDS (London, England)|September 4, 1998
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysisA M Bayoumi, D A Redelmeier
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 4, 2000
Decision analysis with cumulative prospect theoryA M Bayoumi, D A Redelmeier
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 5, 1999
Economic methods for measuring the quality of life associated with HIV infectionA M Bayoumi, D A Redelmeier
European Journal of Neurology|October 14, 2018
EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravisC Barnett, V Bril, A M Bayoumi
Journal of the American Academy of Dermatology|November 26, 1999
Cost-comparison analysis versus cost-effectiveness analysis: an important differenceS Chen, A M Bayoumi, M K Goldstein
Clinical Pharmacology and Therapeutics|July 17, 2007
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?D A Hughes, A M Bayoumi, M Pirmohamed
Journal of the National Cancer Institute|November 4, 2000
Cost-effectiveness of androgen suppression therapies in advanced prostate cancerA M Bayoumi, A D Brown, A M Garber
Kidney International|January 13, 2006
The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysisP A McFarlane, A M Bayoumi, A Pierratos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 5, 2001
The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United StatesG S Zaric, A M Bayoumi, M L Brandeau, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Annals of Internal Medicine|May 23, 1998
The language of case historiesA M Bayoumi, D Bravata
AIDS (London, England)|September 4, 1998
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysisA M Bayoumi, D A Redelmeier
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 4, 2000
Decision analysis with cumulative prospect theoryA M Bayoumi, D A Redelmeier
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 5, 1999
Economic methods for measuring the quality of life associated with HIV infectionA M Bayoumi, D A Redelmeier
European Journal of Neurology|October 14, 2018
EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravisC Barnett, V Bril, A M Bayoumi
Journal of the American Academy of Dermatology|November 26, 1999
Cost-comparison analysis versus cost-effectiveness analysis: an important differenceS Chen, A M Bayoumi, M K Goldstein
Clinical Pharmacology and Therapeutics|July 17, 2007
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?D A Hughes, A M Bayoumi, M Pirmohamed
Journal of the National Cancer Institute|November 4, 2000
Cost-effectiveness of androgen suppression therapies in advanced prostate cancerA M Bayoumi, A D Brown, A M Garber
Kidney International|January 13, 2006
The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysisP A McFarlane, A M Bayoumi, A Pierratos, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 5, 2001
The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United StatesG S Zaric, A M Bayoumi, M L Brandeau, et al.
Pageof 2